Literature DB >> 34668532

Pain-Related Post-Exertional Malaise in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia: A Systematic Review and Three-Level Meta-Analysis.

Ellen E Barhorst1,2, Alexander E Boruch1,3, Dane B Cook1,3, Jacob B Lindheimer1,3,4.   

Abstract

OBJECTIVE: Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM) are two debilitating, moderately comorbid illnesses in which chronic musculoskeletal pain symptoms are prevalent. These individuals can experience post-exertional malaise (PEM), a phenomenon in which symptom severity is worsened for 24 hours or longer after physical stress, but the pain-related component of PEM is not well characterized.
DESIGN: Systematic review and meta-analysis.
METHODS: Case-control studies involving adults with ME/CFS or FM and measuring pain symptoms before and after exposure to a standardized aerobic exercise test were included. Hedges' d effect sizes were aggregated with random-effects models, and potential moderators were explored with meta-regression analysis. Results were adjusted for nesting effects with three-level modeling.
RESULTS: Forty-five effects were extracted from 15 studies involving 306 patients and 292 healthy controls. After adjusting for nesting effects, we observed a small to moderate effect indicating higher post-exercise pain in patients than in controls (Hedges' d = 0.42; 95% confidence interval [CI]: 0.16-0.67). The mean effect was significantly moderated by pain measurement time point (b = -0.19, z = -2.57, P = 0.01), such that studies measuring pain 8-72 hours after exercise showed larger effects (d = 0.71, 95% CI = 0.28-1.14) than did those measuring pain 0-2 hours after exercise (d = 0.32, 95% CI = 0.10-0.53).
CONCLUSIONS: People with ME/CFS and FM experience small to moderate increases in pain severity after exercise, which confirms pain as a component of PEM and emphasizes its debilitating impact in ME/CFS and FM. Future directions include determining mechanisms of pain-related PEM and developing exercise prescriptions that minimize symptom exacerbation in these illnesses. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Keywords:  Exercise Test; Hyperalgesia; Patient-Reported Outcome Measures; Self-Report; Sensation

Mesh:

Year:  2022        PMID: 34668532     DOI: 10.1093/pm/pnab308

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.637


  4 in total

1.  Fibromyalgia and Chronic Fatigue Syndromes: A systematic review and meta-analysis of cardiorespiratory fitness and neuromuscular function compared with healthy individuals.

Authors:  Fabio Zambolin; Pablo Duro-Ocana; Azmy Faisal; Liam Bagley; William J Gregory; Arwel W Jones; Jamie S McPhee
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

2.  Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Greatly Improved Fatigue Symptoms When Treated with Oxygen-Ozone Autohemotherapy.

Authors:  Umberto Tirelli; Marianno Franzini; Luigi Valdenassi; Sergio Pandolfi; Massimiliano Berretta; Giovanni Ricevuti; Salvatore Chirumbolo
Journal:  J Clin Med       Date:  2021-12-22       Impact factor: 4.241

3.  Male vs. Female Differences in Responding to Oxygen-Ozone Autohemotherapy (O2-O3-AHT) in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Authors:  Salvatore Chirumbolo; Luigi Valdenassi; Marianno Franzini; Sergio Pandolfi; Giovanni Ricevuti; Umberto Tirelli
Journal:  J Clin Med       Date:  2021-12-29       Impact factor: 4.241

4.  Cardiopulmonary, metabolic, and perceptual responses during exercise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Multi-site Clinical Assessment of ME/CFS (MCAM) sub-study.

Authors:  Dane B Cook; Stephanie VanRiper; Ryan J Dougherty; Jacob B Lindheimer; Michael J Falvo; Yang Chen; Jin-Mann S Lin; Elizabeth R Unger
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.